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Background: Patients with Sturge-Weber syndrome can have ipsilateral diffuse or circumscribed choroidal
hemangiomas. These hemangiomas have been seen to undergo spontaneous exudative or hemorrhagic retinal
detachments. There is no definitive treatment for these types of retinal detachments, but radiotherapy,
photodynamic therapy, oral propranolol, pegaptinib and bevacizumab have been used.
Case presentation: A 26-year-old male with Sturge-Weber Syndrome developed an exudative retinal detachment
that occurred immediately after taking a supplement containing arginine. The patient was treated with intravitreal
bevacizumab 1.25 mg in 0.05 ml solution. Resolution of the retinal detachment was seen after 4 treatments over a
six-month period.
Conclusions: Arginine and other medications that cause a release of nitric oxide may lead to intravascular leakage
and exudative retinal detachments in patients who have a choroidal hemangioma.
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Sturge-Weber Syndrome is a relatively uncommon neuro-
oculo-cutaneous syndrome. The most noticeable feature is
the nevus flammeus (aka port wine stain) involving der-
matomal distribution of any one or multiple divisions of
the trigeminal nerve. Diffuse or circumscribed chor-
oidal hemangiomas are a common ocular feature of this
syndrome [1] usually appearing unilaterally and ipsilateral
to the cutaneous malformation [2]. A diffuse choroidal
hemangioma is a risk factor for secondary exudative or
hemorrhagic retinal detachment during or after intraocu-
lar surgery [3].
There is no definitive treatment regimen for exudative
retinal detachment in patients with choroidal hemangi-
omas. Treatment options include radiotherapy [4], photo-
dynamic therapy [5], oral propranolol [6], pegaptinib [7],
and bevacizumab [8,9].* Correspondence: TMurray@murraymd.com
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A 26-year-old white male developed a decrease of vision
with associated photopsias in his left eye (OS). The
symptoms developed minutes after he took an over-the-
counter arginine supplement advertised for erectile dys-
function. The patient’s medical history was significant
for Sturge-Weber Syndrome with a left nevus flammeus
affecting the ophthalmic and maxillary division of the
trigeminal nerve. Other than the cutaneous symptoms,
the patient had no hypertension or blood dyscrasias.
Ophthalmologic history was remarkable for a diffuse
choroidal hemangioma in his left eye with associated
mild amblyopia. The patient had no surgical history. At
initial evaluation, the patient was using one drop of
nepafenac 0.1% to the left eye 3 times a day, which was
prescribed by his primary ophthalmologist for the ex-
udative retinal detachment for 5 days. The patient was
not taking any other prescriptions or supplements. The
patient also denies any trauma or strenuous activity pre-
ceding the decrease in vision. The patient’s last ophthal-
mologic exam was in the year prior to the inciting event
with no sign of an exudative retinal detachment as per
the patient’s primary ophthalmologist.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Best-corrected visual acuity was 20/20 right eye (OD) and
20/40 OS. Intraocular pressures were 13 and 15 mmHg,
respectively. Pupils were equally round and reactive. Visual
fields, anterior segment, and extraocular motility were un-
remarkable. External examination was positive for a left fa-
cial nevus flammeus. Indirect ophthalmoscopy of the OD
fundus was unremarkable. The OS was remarkable for a
diffuse, shallow choroidal mass. The cup to disc ratio was
0.3 OD and 0.45 OS. Ocular ultrasonography revealed a
slightly irregular, diffuse, dome-shaped mass 3.5 mm thick
OS with internal reflectivity, consistent with a diffuse chor-
oidal hemangioma; additionally, a thin, highly reflective
membrane suggestive of an overlying exudative retinal de-
tachment was present (Figure 1). Spectral-domain optical
coherence tomography (SD-OCT) confirmed the presence
of subretinal fluid (Figure 2A). Fluorescein angiography
(Figure 3) showed early hyperfluorescence as well as late
phase leakge, which is consistent with an exudative retinal
detachment. The patient was treated with intravitreal
bevacizumab, 1.25 mg in 0.05 mL; six weeks later, SD-
OCT showed a marked decrease of the subretinal fluid
(Figure 2B). Over the next few months, the patient was
treated with further intravitreal Avastin injections with de-
creasing exudate at each visit.
At six months follow-up, the patient had received 4 in-
travitreal doses of bevacizumab due to persistent subret-
inal fluid. Best-corrected visual acuity at that evaluation
was 20/40 OS. Resolution of the exudative retinal de-
tachment can be seen in Figure 2C. The patient was seen
again at 8 months with continued resolution of the ex-
udative retinal detachment.
Conclusion
Diffuse choroidal hemangiomas have been reported in
up to 71% of patients with Sturge-Weber syndrome [9].
Patients with Sturge-Weber syndrome that have port-
wine stains of the eyelids (upper more than lower), bilat-
eral distribution of the port wine stain, or unilateral
port-wine stain involving all three distributions of the
trigeminal nerve have a greater likelihood of having ocular
and neural complications [10]. Sturge-Weber Syndrome
can be associated with glaucomatous changes due toFigure 1 B-scan of both eyes. (A) Normal eye, OD, (B) longitudinal, and
reflectivity representing a diffuse choroidal hemangioma with peripheral reincreased episcleral outflow obstruction [11-13]. Choroidal
hemangiomas are commonly associated to visual acuity
loss due to refractive amblyopia, glaucoma, macular
edema, and exudative retinal detachments [14].
Diffuse choroidal hemangioma remains a diagnostic
challenge. The choroidal hemangiomas in Sturge-Weber
may sometimes be overlooked because of their diffuse na-
ture and because the hemangioma may blend impercept-
ibly with the adjacent choroid. Indirect ophthalmoscopy
shows increased tortuosity of the retinal vasculature as
well as choroidal thickening. Lesions typically present as a
diffusely, deep red, “tomato ketchup” fundus. The actual
lesion will have ill-defined borders and may involve the
entire fundus [2]. Ancillary testing is important in the
diagnosis of diffuse choroidal hemangioma. Fluorescein
angiography typically shows an early diffuse speckled
hyperfluorescent choroidal flush [2]. Echography is
associated with a hyperechoic lesion with high internal re-
flectivity and diffuse choroidal thickening [15]. Optical co-
herence tomography will show enhanced visualization of
the choroid.
Patients with diffuse choroidal hemangiomas are at
higher risk for the development of spontaneous or drug-
induced exudative retinal detachments. Vascular alter-
ations in retina and choroid may play a key role in the
pathogenesis of the detachment [16]. Recent reports
have documented successful treatment of exudative retinal
detachments with intravitreal injection of human
monoclonal antibodies against vascular endothelial growth
factor (anti-VEGF) both as primary and secondary treat-
ments [7,9,17]. This therapy is used to inhibit the forma-
tion of aberrant blood vessels and to decrease vascular
permeability.
The treatment options for an exudative retinal detach-
ment secondary to a choroidal hemangioma include
photodynamic therapy (PDT), intravitreal injection of a
vascular endothelial growth factor inhibitor, like Avastin,
or a combination of both therapies. The choice to use
Avastin only was due to the fact that it is less invasive
and has fewer systemic effects. PDT involves intravenous
administration of chemicals, which have multiple side ef-
fects including, but not limited to the patient not being
allowed in the sun for 72 hours after injection. Avastin is(C) transverse of OS showing diffuse choroidal thickening, and internal
tinal detachment.
Figure 2 SD-OCT with corresponding multicolor images. (A) SD-OCT with corresponding multicolor image of subretinal fluid associated with
hemangioma before treatment. (B) SD-OCT with corresponding multicolor image of subretinal fluid associated with hemangioma after first intravitreal
Avastin treatment, (C) SD-OCT with corresponding multicolor image of subretinal fluid associated with hemangioma after four intravitreal
Avastin treatments.
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[17]. In general, we do not use combination therapy un-
less monotherapy with an intravitreal injection does not
show adequate improvement.
To our knowledge, this is the first case of a patient
with a diffuse choroidal hemangioma that developed anFigure 3 Fluorescein angiography of the left eye. (A) Marked central hy
increased hyperfluorescence indication leakage.exudative retinal detachment associated to arginine
supplementation. Choroidal hemangiomas have been
associated to increased VEGF levels [18]. Arginine is a
chemical precursor to nitric oxide, which causes vasodila-
tion. Arginine may increase ocular venous dilation and de-
crease venous return to the systemic circulation. This canperfluorescence in the venous phase, and (B) late phase showing
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and increase in intraocular pressure.
Erectile dysfunction medications including phospho-
diesterase type 5 inhibitors, such as sildenafil, have been
associated with numerous ocular side effects including
elevation of intraocular pressure, choroidal thickening,
and central serous chorioretinopathy [19-22]. The major
active ingredient of these drugs is an isomer of Arginine.
This causes an increase of systemic nitric oxide, which
leads to the erection, as well as the exudative retinal de-
tachment, as we postulate. Arginine supplementation
may be associated to similar risks in susceptible patients
as it is a precursor to nitric oxide [23]. It is also ex-
tremely well absorbed and can be absorbed even more
quickly with the addition of other supplements. Without
the addition of other supplements, such as glutamine,
arginine has 68% oral bioavailability, its half-life is 0.7-
1.3 hours, and its peak serum time is about 2 hours [24].
There is very little research in regards to the relationship
of arginine/nitric oxide to exudative retinal detachments
due to arginine not being a standard medical treatment.
In patients with diffuse choroidal hemangiomas, treat-
ment with bevacizumab may improve resolution of
subretinal fluid as demonstrated in Figure 2C. Review of
medication history and discontinuation of recently
added vasodilators may play a key role in the manage-
ment of patients with exudative detachments associated
to choroidal hemangiomas. Our treatment plan of mul-
tiple injections of bevacizumab showed that this class of
drugs is useful for treatment of exudative retinal detach-
ment secondary to nitric oxide producing vasodilators.
Though this exudative retinal detachment can be consid-
ered spontaneous, the fact that it occurred in close prox-
imity to the use of a drug from a class that can cause
exudative retinal detachments leads us to conclude that
this was not a spontaneous exudative retinal detach-
ment. There is also the possibility of spontaneous reso-
lution of the exudative retinal detachment which could
have aided Avastin in its resolution.
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